piracetam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
amide type nootrope agents, piracetam derivatives 2197 7491-74-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piracetam
  • 2-Pyrrolidinoneacetamide
  • neuracetam
  • pirazetam
  • nootropil
A compound suggested to be both a nootropic and a neuroprotective agent.
  • Molecular weight: 142.16
  • Formula: C6H10N2O2
  • CLOGP: -1.18
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 63.40
  • ALOGS: 0.53
  • ROTB: 2

Drug dosage:

DoseUnitRoute
2.40 g O
6 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 803.93 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 100 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,SIK2,SIK3,STK33,TEK 28
kinase-selectivity-class BRAF,CSNK2A2,GRK2,MAPK7,STK33,TEK,TTK 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mitochondrial toxicity 70.97 32.89 12 1625 651 90626159
Central nervous system injury 63.82 32.89 9 1628 144 90626666
Splenic injury 53.10 32.89 8 1629 206 90626604
Mitochondrial encephalomyopathy 50.51 32.89 7 1630 98 90626712
Neuroleptic malignant syndrome 49.50 32.89 16 1621 15080 90611730
Hypochromasia 49.08 32.89 8 1629 346 90626464
Hyperchloraemia 48.01 32.89 9 1628 879 90625931
Petechiae 44.84 32.89 15 1622 15726 90611084
Product selection error 43.63 32.89 7 1630 274 90626536
Anisocytosis 42.56 32.89 8 1629 793 90626017
Drug interaction 40.40 32.89 36 1601 276417 90350393
Intestinal pseudo-obstruction 39.58 32.89 8 1629 1155 90625655
Bradycardia 33.23 32.89 20 1617 83827 90542983
Hyperaemia 33.04 32.89 8 1629 2634 90624176

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Parkinsonism 62.94 30.91 19 1026 10604 42609686

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Central nervous system injury 61.18 31.95 9 2474 156 110586660
Mitochondrial toxicity 49.35 31.95 12 2471 3233 110583583
Splenic injury 49.30 31.95 8 2475 269 110586547
Mitochondrial encephalomyopathy 48.17 31.95 7 2476 111 110586705
Myoclonus 43.45 31.95 19 2464 32979 110553837
Hyperchloraemia 42.59 31.95 9 2474 1297 110585519
Hypochromasia 41.75 31.95 8 2475 704 110586112
Product selection error 38.64 31.95 7 2476 454 110586362
Anisocytosis 37.61 31.95 8 2475 1188 110585628
Neuroleptic malignant syndrome 36.54 31.95 17 2466 34042 110552774
Petechiae 35.89 31.95 15 2468 23302 110563514
Speech disorder 34.89 31.95 20 2463 61549 110525267
Parkinsonism 33.24 31.95 14 2469 22173 110564643

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BX03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Other psychostimulants and nootropics
ATC N06BX53 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Other psychostimulants and nootropics
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018697 Nootropic Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent

Related Drugs by ATC class:

N06BX Other psychostimulants and nootropics 19 drugs
acetylcarnitineadrafinilaniracetamcinnarizineciticolinedeanolfipexideidebenonelinopirdinemeclofenoxatenizofenoneoxiracetam show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.28 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000007934 NUI
D01914 KEGG_DRUG
4036333 VANDF
C0031977 UMLSCUI
CHEBI:32010 CHEBI
PZI PDB_CHEM_ID
CHEMBL36715 ChEMBL_ID
DB09210 DRUGBANK_ID
D010889 MESH_DESCRIPTOR_UI
4843 PUBCHEM_CID
2687 INN_ID
4288 IUPHAR_LIGAND_ID
ZH516LNZ10 UNII
8351 RXNORM
NOCODE MMSL
004363 NDDF
322998004 SNOMEDCT_US
395833008 SNOMEDCT_US
ZH516LNZ10 INXIGHT DRUGS

Pharmaceutical products:

None